US53220K5048
US53220K5048
Ligand Pharmaceuticals Incorpor
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 6.02B EUR | 6.3B EUR | 4B EUR | 3.74B EUR |
Enterprise Value | 5.65B EUR | 6.42B EUR | 4.34B EUR | 4.02B EUR |
Valuation Multiples | ||||
Trailing P/E | 31.8x | 31.93x | 26.04x | 22.4x |
Forward P/E | 25.26x | -- | -- | -- |
Price to Sales | 20.71x | 21.67x | 14.57x | 16.78x |
Price to Book | 6.21x | 6.51x | 4.01x | 3.68x |
EV/Revenue | 19.46x | 22.1x | 15.8x | 18.03x |
EV/EBITDA | 42.51x | 40.19x | 28.11x | 32.6x |
Price to FCF (P/FCF) | 43.05x | 52.58x | 35.08x | 57.06x |
EV/FCF | 40.46x | 53.62x | 38.04x | 61.28x |
FCF Yield | 2.32% | 1.9% | 2.85% | 1.75% |